Back to News
Market Impact: 0.15
Arcutis Presents ZORYVE Data At Dermatology Meetings; Stock Up
Source: Nasdaq
Healthcare & Biotech
Arcutis Biotherapeutics announced that new data on ZORYVE (roflumilast) and research on long-term topical corticosteroid use were presented at the EADV Congress and Fall Clinical Dermatology Conference. The report provides no data results or quantified clinical outcomes.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
ARQT0.30
More News
- Teva wins FDA approval for monthly schizophrenia injection Weltruza
- BofA downgrades Alignment Healthcare stock rating on star rating drop
- Humana Stock Jumps on Raised Medicare Advantage Ratings
- Premarket movers: Humana rallies; SpaceX deal sends telco stocks down
- HIMS jumps 7% on peptide tailwind — but Citi sees 17% downside from here
- Alignment Healthcare Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Alignment Healthcare (ALHC)
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- What Is an AI Research Agent?
- Bitcoin's 52% Crash Proves It's a Tech Stock: Here's What That Means for Portfolio Construction